Aliases & Classifications for Depression

MalaCards integrated aliases for Depression:

Name: Depression 25 29 43 63
Depressive Disorder 25 55 73
Major Depressive Disorder 25 73
Unipolar Depression 25 73
Clinical Depression 25 73
Depressive Syndrome 55 73
Major Depression 25 55
Mental Depression 73
Mdd 25

Classifications:



External Ids:

ICD10 33 F32.9

Summaries for Depression

MedlinePlus : 43 Depression is a serious medical illness. It's more than just a feeling of being sad or "blue" for a few days. If you are one of the more than 19 million teens and adults in the United States who have depression, the feelings do not go away. They persist and interfere with your everyday life. Symptoms can include Feeling sad or "empty" Loss of interest in favorite activities Overeating, or not wanting to eat at all Not being able to sleep, or sleeping too much Feeling very tired Feeling hopeless, irritable, anxious, or guilty Aches or pains, headaches, cramps, or digestive problems Thoughts of death or suicide Depression is a disorder of the brain. There are a variety of causes, including genetic, biological, environmental, and psychological factors. Depression can happen at any age, but it often begins in teens and young adults. It is much more common in women. Women can also get postpartum depression after the birth of a baby. Some people get seasonal affective disorder in the winter. Depression is one part of bipolar disorder. There are effective treatments for depression, including antidepressants, talk therapy, or both. NIH: National Institute of Mental Health

MalaCards based summary : Depression, also known as depressive disorder, is related to atypical depressive disorder and endogenous depression, and has symptoms including affective symptoms, behavioral symptoms and schizophrenic language. An important gene associated with Depression is BDNF-AS (BDNF Antisense RNA
The lncRNA BDNF-AS is related to many neurological disorders,including Huntington's disease (HD),schizophrenia,and depression.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Zinc and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Genetics Home Reference : 25 Depression (also known as major depression or major depressive disorder) is a psychiatric disorder that affects mood, behavior, and overall health. It causes prolonged feelings of sadness, emptiness, or hopelessness, and a loss of interest in activities that were once enjoyed. People with depression may also have changes in appetite (leading to overeating or not eating enough), changes in sleeping patterns (sleeping too much or not being able to sleep), loss of energy, and difficulty concentrating. Although depression is considered primarily a mental health disorder, it can also have physical features including headaches, other unexplained aches and pains, unusually slow or fast movements, and digestive problems. To be diagnosed with depression, an individual must have signs and symptoms nearly every day for at least 2 weeks. However, the features of this condition vary widely.

PubMed Health : 63 About depression: We all feel sad or lethargic every now and then. And we have all felt down or even desperate at some point in our lives. These phases are a normal part of life, and people usually feel better again after a while. Things are different for people who have depression. Their sadness and negative thoughts last longer and overshadow all of their thoughts and actions. Depression can arise without any triggering events or for no apparent reasons. People often feel like they are stuck in a black hole. They feel cheerless, lack motivation and self-confidence, and think of themselves as worthless. This can make it difficult to do everyday things like going to work or studying. Friends, family and hobbies are often neglected. They don't sleep well.Depression can also make family and friends feel worried, anxious and helpless. Often they want to help but don't know how. It's not always easy for them to tell whether it's a passing phase or a serious illness.

Related Diseases for Depression

Diseases related to Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1010)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 34.7 CRH MAOA SLC6A4
2 endogenous depression 34.5 BDNF CRH MAOA SLC6A4
3 postpartum depression 34.2 BDNF CRH HTR1A MAOA SLC6A4
4 dysthymic disorder 32.9 HTR2A MAOA SLC6A4
5 fibromyalgia 32.6 CRH HTR2A SLC6A4
6 eating disorder 32.5 BDNF CRH HTR2C SLC6A4
7 bulimia nervosa 32.3 BDNF HTR2A MAOA SLC6A4
8 schizoaffective disorder 32.2 BDNF DISC2 HTR2A SLC6A4
9 bipolar i disorder 32.0 BDNF HTR1A HTR2A HTR2C SLC6A4
10 irritable bowel syndrome 31.9 CRH CRHR1 SLC6A4 TPH1
11 mental depression 31.8 BDNF CRH HTR1A HTR2A HTR2C MAOA
12 autism spectrum disorder 31.6 BDNF DISC2 HTR2A SLC6A4
13 major depressive disorder 31.2 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
14 social phobia 31.1 HTR1A MAOA SLC6A4
15 substance abuse 31.0 BDNF MAOA SLC6A4
16 agoraphobia 30.9 HTR1A MAOA SLC6A4
17 substance dependence 30.8 BDNF MAOA SLC6A4
18 anorexia nervosa 30.8 BDNF CRH HTR2A SLC6A4
19 drug dependence 30.7 BDNF CRH SLC6A4
20 oppositional defiant disorder 30.7 MAOA SLC6A4 TPH2
21 conduct disorder 30.7 MAOA SLC6A4 TPH1
22 pathological gambling 30.6 HTR2A MAOA SLC6A4
23 migraine with or without aura 1 30.6 HTR1A HTR2A HTR2C MAOA SLC6A4 TPH1
24 premature ejaculation 30.6 HTR1A HTR2C SLC6A4
25 parkinson disease, late-onset 30.6 BDNF GRM1 HTR1A HTR2A MAOA NOS1
26 paranoid schizophrenia 30.4 BDNF HTR2A MAOA SLC6A4 TPH2
27 fragile x syndrome 30.4 BDNF GRIA1 GRM1 SLC6A4
28 serotonin syndrome 30.3 HTR1A HTR2A MAOA SLC6A4
29 post-traumatic stress disorder 30.3 BDNF CRH HTR2A MAOA NR3C1 SLC6A4
30 tobacco addiction 30.3 HTR2A MAOA TPH1
31 kleptomania 30.3 HTR1A MAOA SLC6A4
32 borderline personality disorder 30.2 BDNF HTR1A HTR2A HTR2C MAOA NR3C1
33 anxiety 30.2 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
34 autism 30.1 BDNF HTR1A HTR2A MAOA SLC6A4 TPH2
35 hypoactive sexual desire disorder 30.1 HTR1A HTR2A
36 chronic fatigue syndrome 30.1 CRH HTR1A MAOA NR3C1 SLC6A4 TPH2
37 generalized anxiety disorder 30.0 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
38 early-onset schizophrenia 30.0 BDNF HTR2A MAOA SLC6A4
39 phobic disorder 30.0 HTR1A MAOA SLC6A4
40 periodic limb movement disorder 29.7 HTR1A HTR2A HTR2C SLC6A4
41 personality disorder 29.6 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
42 ocular dominance 29.5 BDNF HTR2C NOS1
43 obsessive-compulsive disorder 29.4 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
44 attention deficit-hyperactivity disorder 29.2 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
45 alcohol dependence 29.2 BDNF CRHR1 HTR1A HTR2A HTR2C MAOA
46 panic disorder 29.0 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
47 bipolar disorder 28.9 BDNF CRH DISC2 GRIA1 GRIA3 GRM1
48 mood disorder 28.9 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
49 psychotic disorder 28.8 BDNF HTR1A HTR2A HTR2C NOS1 SLC6A4
50 sudden infant death syndrome 28.6 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1

Graphical network of the top 20 diseases related to Depression:



Diseases related to Depression

Symptoms & Phenotypes for Depression

UMLS symptoms related to Depression:


affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, dejection emotional, depressed reaction, depression aggravated, depressed - symptom

GenomeRNAi Phenotypes related to Depression according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 BDNF CRHR1 GRIA2 GRID2 HTR2C MAOA

MGI Mouse Phenotypes related to Depression:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
2 homeostasis/metabolism MP:0005376 10.31 CRH CRHR1 GRIA1 GRIA2 GRID2 GRM1
3 growth/size/body region MP:0005378 10.27 NOS1 NR3C1 SLC6A4 TPH1 TPH2 BDNF
4 nervous system MP:0003631 10.16 GRIA3 GRID2 GRM1 HTR1A HTR2C MAOA
5 mortality/aging MP:0010768 10.15 BDNF CRHR1 GRIA2 GRIA3 GRID2 GRM1
6 integument MP:0010771 10.14 HTR2C NR3C1 SLC6A4 TPH1 TPH2 BDNF
7 adipose tissue MP:0005375 10.04 CRH GRM1 HTR2C NOS1 NR3C1 TPH1
8 muscle MP:0005369 9.92 GRID2 GRM1 HTR2A HTR2C NOS1 NR3C1
9 no phenotypic analysis MP:0003012 9.9 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
10 normal MP:0002873 9.61 BDNF CRH CRHR1 GRIA1 GRIA2 NOS1
11 respiratory system MP:0005388 9.17 BDNF CRH CRHR1 NOS1 NR3C1 TPH1

Drugs & Therapeutics for Depression

PubMedHealth treatment related to Depression: 63

Many people who have depression find it hard to accept that fact. One possible reason for this is that they are ashamed about having a mental health problem and don't want their friends, family and colleagues to find out. Some people don't want to have treatment as a result. But treatment can often shorten depressive episodes and relieve people's symptoms.There are various treatment options for depression. The main treatments are psychological treatment, such as cognitive behavioral therapy, and/or medication. Which type of treatment is the most appropriate, where it should take place and how long it lasts will depend on several factors, including how severe the person’s depression is, their personal circumstances, and how their symptoms develop over time. People can talk to a therapist about the advantages and disadvantages of the possible treatments, as well as what they expect from treatment and any fears they might have.

Drugs for Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
2
Naproxen Approved, Vet_approved Phase 4,Phase 2,Not Applicable 22204-53-1 1302 156391
3
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
4
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
5
Exenatide Approved, Investigational Phase 4,Phase 2 141758-74-9 15991534
6
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 1 50-53-3 2726
7
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85650-52-8, 61337-67-5 4205
8
Ranibizumab Approved Phase 4,Phase 1 347396-82-1 459903
9
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
10
Copper Approved, Investigational Phase 4,Phase 3 7440-50-8 27099
11
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
12
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
13
Remifentanil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 132875-61-7 60815
14
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
15
Simvastatin Approved Phase 4,Phase 2,Phase 1 79902-63-9 54454
16
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
17
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
18
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
19
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19982-08-2 4054
20
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
21
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
22
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 249296-44-4 5310966
23
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 19794-93-5 5533
24
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 169590-42-5 2662
25
Imipramine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-49-7 3696
26
Moclobemide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 71320-77-9 4235
27
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24219-97-4 4184
28
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
29
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
30
Mannitol Approved, Investigational Phase 4,Phase 2,Not Applicable 69-65-8 453 6251
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
32
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
33
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-36-2 5760 446220
34
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 73590-58-6 4594
35
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3,Not Applicable 13422-51-0 11953898 44475014
36
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10118-90-8 5281021
37
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
38
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
39
Trimipramine Approved Phase 4,Phase 3 739-71-9 5584 4055
40
Nortriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72-69-5 4543
41
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
42
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 52485-79-7 40400 644073
43
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
44
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
45
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
46
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68693-11-8 4236
47
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
48
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-41-0 1775
49
Drospirenone Approved Phase 4,Phase 2,Not Applicable 67392-87-4 68873
50
Tibolone Approved, Investigational Phase 4,Phase 1 5630-53-5

Interventional clinical trials:

(show top 50) (show all 10203)
# Name Status NCT ID Phase Drugs
1 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
2 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
3 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
4 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
5 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
6 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
7 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
8 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
9 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
10 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
11 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
12 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
13 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
14 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
15 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
16 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
17 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
18 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
19 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
20 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
21 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
22 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
23 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
24 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
25 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
26 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
27 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
28 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
29 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
30 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
31 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
32 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
33 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
34 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
35 Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder Unknown status NCT01696617 Phase 4 Aripiprazole 6-week group;Aripiprazole 8-week group
36 Lexapro®'s Efficacy After Dose Escalation in Remission Study Unknown status NCT01594866 Phase 4 escitalopram;escitalopram
37 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
38 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
39 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
40 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
41 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
42 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
43 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
44 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
45 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
46 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
47 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
48 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
49 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
50 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine

Search NIH Clinical Center for Depression

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Depression

Genetic tests related to Depression:

# Genetic test Affiliating Genes
1 Depression 29

Anatomical Context for Depression

MalaCards organs/tissues related to Depression:

41
Brain, Breast, Heart, Testes, Lung, Spinal Cord, Prostate

Publications for Depression

Articles related to Depression:

(show top 50) (show all 10500)
# Title Authors Year
1
Could we use parent report as a valid proxy of child report on anxiety, depression, and distress? A systematic investigation of father-mother-child triads in children successfully treated for leukemia. ( 29049860 )
2018
2
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety. ( 28216088 )
2018
3
Understanding Spreading Depression from Headache to Sudden Unexpected Death. ( 29449828 )
2018
4
Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-I+ derived from adipocyte. ( 29976395 )
2018
5
The Cognitive Reserve Should Be Controlled When Using Neuroimaging to Assess Relapse in Major Depressive Disorder-Reply. ( 29955762 )
2018
6
'Happy that someone cared'-Non-native-speaking immigrant mothers' experiences of participating in screening for postpartum depression in the Swedish child health services. ( 29804463 )
2018
7
Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. ( 28972930 )
2018
8
Relationship Between Postpartum Depression and Psychological and Biological Variables in the Initial Postpartum Period. ( 29423586 )
2018
9
Alterations in Serum BDNF and GDNF Levels after 12 Weeks of Antidepressant Treatment in Female Outpatients with Major Depressive Disorder. ( 29945425 )
2018
10
The Cognitive Reserve Should Be Controlled When Using Neuroimaging to Assess Relapse in Major Depressive Disorder. ( 29955790 )
2018
11
Burden of Depression among Working-Age Adults with Rheumatoid Arthritis. ( 29971163 )
2018
12
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features). ( 29943445 )
2018
13
Anxiety and Depression: A Cross-sectional Survey among Parents of Children with Cancer. ( 29440813 )
2018
14
Functional brain abnormalities in major depressive disorder using the Hilbert-Huang transform. ( 29427063 )
2018
15
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
16
Postpartum Depression and Its Long-term Impact on Children: Many New Questions. ( 29387871 )
2018
17
Passive smoking and postpartum depression among Chinese women: a prospective cohort study in Tianjin, China. ( 29924720 )
2018
18
Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity. ( 28985587 )
2018
19
Development of a Strategic Tool for Shared Decision-Making in the Use of Antidepressants among Patients with Major Depressive Disorder: A Focus Group Study. ( 29970848 )
2018
20
Aspects of Additional Psychiatric Disorders in Severe Depression/Melancholia: A Comparison between Suicides and Controls and General Pattern. ( 29933593 )
2018
21
Prevalence of childhood trauma and correlations between childhood trauma, suicidal ideation, and social support in patients with depression, bipolar disorder, and schizophrenia in southern China. ( 29223913 )
2018
22
Underestimated caregiver burden by cancer patients and its association with quality of life, depression and anxiety among caregivers. ( 29333736 )
2018
23
Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. ( 29320524 )
2018
24
Review of biologic and behavioral risk factors linking depression and peripheral artery disease. ( 29801423 )
2018
25
A Dyadic Approach to Infertility Stress, Marital Adjustment, and Depression on Quality of Life in Infertile Couples. ( 29436974 )
2018
26
Predicting the Effectiveness of Work-Focused CBT for Common Mental Disorders: The Influence of Baseline Self-Efficacy, Depression and Anxiety. ( 29450678 )
2018
27
Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. ( 29800939 )
2018
28
Integrating Optimal Screening, Intervention, and Referral for Postpartum Depression in Adolescents. ( 29779510 )
2018
29
Patterns of symptom change in major depression: Classification and clustering of long term courses. ( 29980128 )
2018
30
Preliminary Psychometric Testing of the Postpartum Depression Predictors Inventory-Revised (PDPI-R) in Portuguese Women. ( 29327321 )
2018
31
The Effects of Caregiver Depression on Childhood Asthma: Pathways and Mechanisms. ( 29981440 )
2018
32
The role of tryptophan metabolism in postpartum depression. ( 29307018 )
2018
33
Opioid Addiction in Pregnancy: Does Depression Negatively Impact Adherence With Prenatal Care? ( 29068826 )
2018
34
Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: Possible association with major depressive disorder? ( 29414551 )
2018
35
Prevalence of cognitive impairment in major depression and bipolar disorder. ( 29345037 )
2018
36
Major depressive disorder: Longitudinal analysis of impact on clinical and behavioural outcomes in Uganda. ( 29424787 )
2018
37
Screening for Postpartum Depression in American Indian/Alaska Native Women: A Comparison of Two Instruments. ( 29889949 )
2018
38
A machine learning framework involving EEG-based functional connectivity to diagnose major depressive disorder (MDD). ( 28702811 )
2018
39
Validation of the Kutcher Adolescent Depression Scale in a Caribbean student sample. ( 29976555 )
2018
40
Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study. ( 29914603 )
2018
41
Identification of Distinct Latent Classes Related to Sleep, PTSD, Depression, and Anxiety in Individuals Diagnosed With Severe Alcohol Use Disorder. ( 29377714 )
2018
42
Subconstructs of the Edinburgh Postpartum Depression Scale in a postpartum sample in Mexico City. ( 29879609 )
2018
43
The impact of depressive symptoms on the clinical presentation of Persistent Delusional Disorder. ( 29248867 )
2018
44
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. ( 29806492 )
2018
45
The association between pre-pregnancy obesity and screening results of depression for all trimesters of pregnancy, postpartum and 1 year after birth: a cohort study. ( 28212108 )
2018
46
Data-Driven Clustering Reveals a Link Between Symptoms and Functional Brain Connectivity in Depression. ( 29980494 )
2018
47
Depression and distress in burning mouth syndrome: A case control study. ( 29460523 )
2018
48
Administration of Allium cepa L. bulb attenuates stress-produced anxiety and depression and improves memory in male mice. ( 29178012 )
2018
49
Major depressive disorder and access to health services among people who use illicit drugs in Vancouver, Canada. ( 29351757 )
2018
50
Psychoeducation against depression, anxiety, alexithymia and fibromyalgia: a pilot study in primary care for patients on sick leave. ( 29693478 )
2018

Variations for Depression

Copy number variations for Depression from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 30014 1 239103312 239231293 Duplication RGS7 Depressive disorder
2 46482 10 81631178 81930681 Duplication ANXA11